Document:

Exhibit
10.1(c)

 

SECOND
AMENDMENT TO CREDIT AGREEMENT

 

This
Second Amendment to Credit Agreement (as the same may from time to time be amended, restated, supplemented or otherwise modified, this
“Amendment”) is made as of September 30, 2021 by and among TRILLIUM HEALTHCARE-OPS, LLC (f/k/a FAIRWAY HEALTHCARE
PROPERTIES, LLC), ASSISTED 4 LIVING, INC., ASSISTED 4 LIVING CONSULTING, LLC (f/k/a TRILLIUM HEALTHCARE CONSULTING), LLC,
IANE PROPERTIES I, LLC, IANE PROPERTIES II, LLC and GREENSIDE HEALTHCARE PROPERTIES, LLC, each a Florida limited
liability company, (each as a “Corporate Guarantor”), each of the parties listed on Annex A attached hereto
(together with such other Persons joined thereto as Borrower from time to time, individually and collectively, “Borrower”),
and GEMINO HEALTHCARE FINANCE, LLC d/b/a SLR HEALTHCARE ABL, a Delaware limited liability company, as lender (“Lender”).

 

BACKGROUND

 

A.
Borrower, each Corporate Guarantor, Lender and the other parties signatory thereto, are parties to a certain Credit Agreement dated as
of May 9, 2019 (as the same may from time to time be further amended, restated, supplemented or otherwise modified, collectively, the
“Credit Agreement”) pursuant to which Borrower established certain financing arrangements with Lender. The Credit
Agreement and all instruments, documents and agreements executed in connection therewith, or related thereto are referred to herein collectively
as the “Existing Loan Documents.” All capitalized terms not otherwise defined herein shall have the meaning ascribed
thereto in the Credit Agreement.

 

B.
Borrower has requested and Lender has agreed to, among other things, (i) consent to the “Requested Action” (as defined herein)
and (ii) amend the terms and conditions of the Existing Loan Documents, each pursuant to the terms and conditions of this Amendment.

 

NOW,
THEREFORE, with the foregoing Background incorporated by reference and made a part hereof and intending to be legally bound, the
parties hereto hereby agree as follows:

 

1.
Consent to Release of Certain Guarantors. Borrower has requested that Lender consent to, notwithstanding anything to the contrary
contained in the Credit Agreement or any Loan Document, the release of Trillium Healthcare Group, LLC, a Florida limited liability company
(“Trillium Healthcare”), and Gregory Shayne Bench, Shari C. Bench, Richard T. Mason, and Christine L. Mason, each
an individual resident of the State of Florida (individually and collectively, the “Individual Guarantor”; together
with Trillium Healthcare, individually and collectively, the “Released Guarantor”), from any and all of such Released
Guarantor’s obligations under the applicable Guaranty Agreement and any other the Loan Documents (collectively, the “Requested
Action”). Lender hereby consents to, acknowledges and approves the Requested Action such that it shall not constitute an Event
of Default under the Credit Agreement. The foregoing consent is also expressly limited to the Requested Action and shall not affect any
breach of any Loan Documents related to any action not described in this Amendment. Upon receipt of the Borrower’s countersignature
hereto and compliance with the terms and conditions of this Amendment, each Released Guarantor shall be released from all of such Released
Guarantor’s obligations pursuant to the terms and conditions of the applicable Guaranty Agreement and any other Loan Documents.

 

2.
Amendment. The Credit Agreement is hereby amended in the following manner:

 

(a)
All references to “Trillium Healthcare Consulting, LLC” in the Credit Agreement and any other Loan Documents are hereby amended
and restated to read as follows: “Assisted 4 Living Consulting, LLC (f/k/a Trillium Healthcare Consulting, LLC)”.

 

(b)
All references to “Fairway Healthcare Properties, LLC” in the Credit Agreement and any other Loan Documents are hereby amended
and restated to read as follows: “Trillium Healthcare – OPS, LLC (f/k/a Fairway Healthcare Properties, LLC)”.

 

    	 

     

    

 

(c)
Section 2.01(a) of the Credit Agreement is hereby amended and restated in its entirety to read as follows:

 

“(a)
Subject to the terms and conditions of this Agreement, Lender hereby establishes for benefit of Borrower a credit facility (“Credit
Facility”) which shall include Advances which may be extended by Lender to or for the benefit of Borrower from time to time
hereunder in the form of revolving loans (“Revolving Loans”) consisting of a line of credit facility which shall be
made available to Borrower on the Closing Date in an aggregate principal amount equal to the Initial Revolving Loan Commitment. After
the Second Amendment Effective Date, so long as no Default or Event of Default exists and subject to the terms of this Agreement and
with the prior written consent of Lender, the Revolving Commitment may be increased upon the written request of Borrower (which such
request shall be made at least thirty (30) days prior to the proposed effective date of such Additional Tranche) to Lender to activate
an Additional Tranche; provided, however, in no event shall the sum of the Revolving Loan Commitment (including the aggregate amount
of all activated Additional Tranches) exceed the Maximum Revolver Amount. The aggregate outstanding amount of all Advances shall not,
at any time, exceed the Revolving Loan Commitment; and the aggregate outstanding amount of all Revolving Loans shall not, at any time,
exceed the Borrowing Base. In no event shall the initial principal amount of any Revolving Loan be less than $25,000.00. Subject to such
limitation, the outstanding balance of all Revolving Loans may fluctuate from time to time, to be reduced by repayments made by Borrower,
to be increased by future Revolving Loans which may be made by Lender. If the aggregate outstanding amount of all Revolving Loans exceeds
the Borrowing Base, or if the aggregate outstanding amount of all Advances (whether in the form of Revolving Loans or otherwise) exceeds
the Revolving Loan Commitment, Borrower shall immediately repay such excess in full pursuant to Section 2.05(b) hereof. Lender has the
right at any time, and from time to time, to set aside reasonable reserves against the Borrowing Base in such amounts as it may deem
appropriate. The Obligations of Borrower under the Credit Facility and this Agreement are joint and several and shall at all times be
absolute and unconditional.”

 

(d)
Section 2.01(b) of the Credit Agreement is hereby amended and restated in its entirety to read as follows:

 

“(b)
At Closing, Borrower shall execute and deliver a promissory note to Lender in the principal amount of the Initial Revolving Loan Commitment
(as may be amended, modified or replaced from time to time, the “Revolving Note”). Upon activation of any Additional
Tranche in accordance with Section 2.01(a) hereof, Borrower shall deliver to Lender an amended and restated Revolving Note evidencing
the Activated Facility Commitment. The Revolving Note shall evidence Borrower’s joint and several, absolute and unconditional obligation
to repay Lender for all Revolving Loans made by Lender under the Credit Facility, with interest as herein and therein provided. Each
and every Revolving Loan under the Credit Facility shall be deemed evidenced by the Revolving Note, which is deemed incorporated herein
by reference and made a part hereof. The Revolving Note shall be substantially in the form set forth in Exhibit 2.01(b) attached
hereto and made a part hereof.”

 

    	2

     

    

 

(e)
Section 2.01(d) of the Credit Agreement is hereby amended and restated in its entirety to read as follows:

 

“(d)
The initial term of the Credit Facility (the “Initial Term”) shall expire on September 29, 2023. All Revolving Loans
shall be repaid on or before the earlier of the last day of the Initial Term or upon termination of the Credit Facility or termination
of this Agreement (the “Maturity Date”). After the Maturity Date no further Revolving Loans shall be available from
Lender.”

 

(f)
Section 2.03(a) of the Credit Agreement is hereby amended and restated in its entirety to read as follows:

 

“(a)
Each Revolving Loan shall bear interest on the outstanding principal amount thereof from the date made until such Revolving Loan is paid
in full, at a rate per annum equal to the LIBOR Rate plus the Applicable Margin (together, the “Interest Rate”). The
Interest Rate on all amounts outstanding under the Credit Facility shall be adjusted daily based on any changes in the LIBOR Rate.”

 

(g)
Section 2.03(c) of the Credit Agreement is hereby amended and restated in its entirety to read as follows:

 

“(c)
Should the Credit Facility be terminated for any reason prior to the last day of the Initial Term, in addition to repayment of all Obligations
then outstanding and termination of Lender’s commitment hereunder, Borrower shall unconditionally be obligated to pay at the time
of such termination, a fee (the “Termination Fee”) in an amount equal to the following percentage of the Revolving Loan Commitment:
two percent (2%), if such early termination occurs on or prior to the first annual anniversary of the Second Amendment Effective Date;
and one percent (1%) if such early termination occurs after the first annual anniversary of the Second Amendment Effective Date but prior
to the thirtieth (30th) day before the last day of the Initial Term.”

 

(h)
Section 2.03(d) of the Credit Agreement is hereby amended and restated in its entirety to read as follows:

 

“(d)
Borrower shall unconditionally pay to Lender a fee (the “Unused Line Fee”) equal to one-half of one percent (0.50%)
per annum of the unused portion of the Credit Facility, which fee shall be calculated and payable monthly, in arrears. The unused portion
of the Activated Facility Commitment shall be the difference between (i) the Activated Facility Commitment and (ii) the greater of (x)
the average daily outstanding balance of the Revolving Loans during each month (or portion thereof, as applicable), and (y) the Minimum
Balance which fees shall be calculated and payable monthly, in arrears.”

 

(i)
Section 2.03(e) of the Credit Agreement is hereby amended and restated in its entirety to read as follows:

 

“(e)
Borrower shall pay Lender a collateral monitoring fee (“Collateral Monitoring Fee”) equal to one percent (1.00%) per
annum of the average Borrowing Base during the prior month (or portion thereof, as applicable).”

 

    	3

     

    

 

(j)
Section 2.05(b) of the Credit Agreement is hereby amended and restated in its entirety to read as follows:

 

“(b)
If at any time the aggregate principal amount of all Revolving Loans outstanding exceeds the Borrowing Base then in effect (including
as a result of the portion of the Borrowing Base attributable to the Omega Tenants exceeding the amount permitted pursuant to the proviso
in the definition of “Borrowing Base”) or the aggregate of all Advances exceeds the Activated Facility Commitment, in each
case, Borrower shall immediately make such principal prepayments of the Revolving Loans (subject to the terms of Section 2.03(c)) as
is necessary to eliminate such excess.”

 

(k)
Section 2.07(f) of the Credit Agreement is hereby amended and restated in its entirety to read as follows:

 

“(f)
Prior to the occurrence of an Event of Default, on each Settlement Date, Lender shall cause all Collections deposited and/or transferred
to the Collection Account since the last Settlement Date to be disbursed in the following order of priority (for purposes of calculating
interest, all funds deposited in the Collection Account for application to any Revolving Loans shall be subject to a five (5) Business
Day clearance period):

 

(i)
to Lender, any costs and Expenses of Lender required to be paid or reimbursed by Borrower under this Agreement or under any of the other
Loan Documents;

 

(ii)
to Lender, in the amount of any Borrowing Base Deficiency, if any, to be applied against the Obligations;

 

(iii)
subject to Section 2.03(c), to Lender, the amount of any prepayment of principal of which Borrower has given at least two (2) Business
Days’ prior notice to Lender; and

 

(iv)
to to Lender, to be applied to any Advances outstanding under the Revolving Loans.

 

In
addition, on each Settlement Date, so long as no Event of Default shall have occurred and remain outstanding, Lender shall disburse to
Borrower the amount, if any, by which the collected balance in the Collection Account exceeds the aggregate outstanding principal amount
of the Advances and all interest and other amounts that will be payable on or before the next Settlement Date.”

 

(l)
Section 2.09 of the Credit Agreement is hereby amended and restated in its entirety to read as follows:

 

“2.09.
Fees. As of the Closing, Lender has fully earned, (a) and Borrower shall have paid to Lender a non-refundable commitment fee (the
“Initial Commitment Fee”) equal to Seventy Five Thousand and No/100 Dollars ($75,000) which shall be paid in three
equal payments of Twenty-Five Thousand and No/100 Dollars ($25,000.00) with the first of such payments being made on the first annual
anniversary of the Closing Date and the next two such payments shall be paid on each of the next two annual anniversaries of the Closing
Date; provided that any remaining unpaid portion of the Commitment Fee outstanding on the Maturity Date shall be due and owing on the
Maturity Date and (b) a good-faith deposit for closing costs in the amount of Thirty Eight Thousand and No/100 Dollars ($38,000) and
a deposit for diligence fees in the amount of Twenty-Five Thousand and No/100 Dollars ($25,000.00), each of which such deposits in this
subsection (b) shall be credited against the Expenses for which Borrower is responsible pursuant to Section 9.05 hereof. As of funding
of any Additional Tranche, Lender shall have fully earned, and Borrower shall have paid to Lender, an additional non-refundable commitment
fee (together with the Initial Commitment Fee, the “Commitment Fee”) equal to one percent (1.00%) of the amount of
the then activated Additional Tranche, which shall be deemed non-refundable when paid.”

 

    	4

     

    

 

(m)
The first sentence of Section 3.01 of the Credit Agreement is hereby amended and restated in its entirety to read as follows:

 

“3.01
Description. To secure the prompt payment and performance in full when due, whether by lapse of time, acceleration, mandatory
prepayment or otherwise, of the Obligations, each Loan Party (other than any Excluded Subsidiary) hereby grants to Lender a continuing
security interest in, and a right to set off against, any and all right, title and interest of such Loan Party (other than any Excluded
Subsidiary) in and to all of the following, whether now owned or existing or owned, acquired, or arising hereafter (collectively, the
“Collateral”):

 

(a)
all Accounts; (b) all cash and currency; (c) all Chattel Paper; (d) those certain Commercial Tort Claims set forth on Schedule 5.23
hereto; (e) all Deposit Accounts; (f) all Documents; (g) all Equipment; (h) all Fixtures; (i) all General Intangibles; (j) all Instruments;
(k) all Inventory; (l) all Investment Property; (m) all Letter-of-Credit Rights; (n) all Goods; (o) all oil, gas or other minerals before
extraction; (p) all pledged equity (other than any equity in any Excluded Subsidiary); (q) all other Property and assets owned by such
Loan Party (other than any Excluded Subsidiary); and (r) all collections, Accessions, receipts and all Proceeds of any and all of the
foregoing.”

 

(n)
Section 6.06(a) of the Credit Agreement is hereby amended and restated in its entirety to read as follows:

 

“(a)
Borrower and each Holding Entity (on a consolidated basis) shall maintain at all times a Fixed Charge Coverage Ratio of at least 1.00
to 1:00 measured quarterly (i) on an Annualized Basis commencing with the three months ending March 31, 2022, (ii) on an Annualized Basis
for the six months ending June 30, 2022, (iii) on an Annualized Basis for the nine months ending September 30, 2022, and (iv) on a trailing
twelve-month basis for the fiscal quarter ending December 31, 2022 and for each fiscal quarter thereafter.”

 

(o)
Section 6.07(a)) of the Credit Agreement is hereby amended and restated in its entirety to read as follows:

 

“(a)
Financial Statements and Collateral Reports.

 

(i)
as soon as available, but in any event within one hundred twenty (120) days after the end of each fiscal year of Parent, financial statements
of Parent for such year which present fairly Parent’s financial condition, including the balance sheet of Parent as at the end
of such fiscal year and an income statement for such fiscal year, all on a consolidated and consolidating basis, setting forth in the
consolidated statements in comparative form, the corresponding figures as at the end of and for the previous fiscal year, all in reasonable
detail, including all supporting schedules, and audited and accompanied by a report and opinion of independent public accountants of
recognized standing, selected by Parent and reasonably satisfactory to Lender, which report and opinion shall be prepared in accordance
with generally accepted auditing standards and shall not be subject to any “going concern” or like qualification or exception
or any qualification or exception as to the scope of such audit;

 

    	5

     

    

 

(ii)
as soon as available, but in any event within forty-five (45) days after the end of each month, each Borrower’s and each Holding
Entity’s internally prepared monthly consolidated and consolidating financial statements, along with year-to-date information,
including a balance sheet and income statement with respect to the periods measured;

 

(iii)
promptly upon request, such other information concerning Borrower and or any Holding Entity as Lender may from time to time request including
Medicare and Medicaid cost reports and audits, annual reports, security law filings and reports to any security holders;

 

(iv)
as soon as available, but in any event no later than thirty (30) days after the first day of each fiscal year, annual consolidated and
consolidating financial projections for Borrower and each Holding Entity for such year, including an income statement prepared on a monthly
basis and such other consolidated and consolidating financial projections as Lender may reasonably request;

 

(v)
contemporaneously with delivery of the annual financial statements referred to in clause (i) above, management reports detailing key
census data for Borrower and a good-standing certificate from Borrower’s, each Holding Entity’s and Corporate Guarantor’s
jurisdiction of organization evidencing that such parties remain in good standing in, and continues to be organized under the laws of,
such jurisdiction;

 

(vi)
on the last business day of every month, evidence satisfactory to Lender that all bed taxes and federal and state taxes, including, without
limitation, payroll taxes, that are due have been paid in full, including without limitation copies of the most recently filed Form 941
for each Borrower, each Holding Entity and Corporate Guarantor together with evidence of such payment; and

 

(vii)
such other data, reports, statements and information (financial or otherwise), as Lender may reasonably request.”

 

(p)
Section 7.13 of the Credit Agreement is hereby amended and restated in its entirety to read as follows:

 

“7.13.
Limitations on Corporate Guarantor. No Corporate Guarantor (other than Parent or Assisted 4 Living Consulting, LLC (f/k/a Trillium
Healthcare Consulting, LLC)) shall, directly or indirectly, engage in any business or conduct any activity, other than activities incidental
to (i) its ownership of the Equity Interests of Borrower, any Excluded Subsidiary or any other Corporate Guarantor, (ii) the maintenance
of its corporate existence, or that of any direct or indirect subsidiary, (iii) its, or any direct or indirect subsidiary’s, legal,
tax, accounting and general administrative matters, and (iv) the transactions contemplated by the Master Lease and entering into and
performing its obligations under the Management Agreement and the Loan Documents. No Corporate Guarantor (other than Parent) shall have
any direct Subsidiaries other than Borrower, any Excluded Subsidiary or any other Corporate Guarantor..”

 

    	6

     

    

 

(q)
Section 8.02 of the Credit Agreement is hereby amended and restated in its entirety to read as follows:

 

“8.02
Cure. Nothing contained in this Agreement or the Loan Documents shall be deemed to compel Lender to accept a cure of any Event
of Default hereunder after the expiration of the cure periods provided herein, if any. Notwithstanding anything to the contrary contained
in this Agreement, in the event Borrower fails to comply with Section 6.06(a) of this Agreement, Borrower has the right to cure
such failure within the Equity Cure Period through one or more Capital Infusions (the “Equity Cure”); provided that
(i) notice of Borrower’s irrevocable election to make an Equity Cure shall be delivered to Agent no later than the day on which
financial statements are required to be delivered for the applicable month or Fiscal Quarter, as applicable, (ii) an Equity Cure shall
not be made more than twice in any period of twelve (12) consecutive months (and shall not include two consecutive periods of Equity
Cures), (iii) the amount of any Equity Cure will be no greater than the amount required to cause the Loan Parties to be in compliance
with such covenants, (iv) all Equity Cures will be disregarded for purposes of the calculation of EBITDAR for all other purposes, including
calculating basket levels, pricing and other items governed by reference to EBITDAR, and (v) there shall be no more than three (3) Equity
Cures made in the aggregate after the Closing Date. Pursuant to the exercise by Borrower of such Equity Cure, the calculation of EBITDAR
solely as used in the financial covenant set forth in Section 6.06(a) of this Agreement shall be recalculated giving effect to
the following pro forma adjustments:

 

	 	(a)	shall
    be increased, solely for the purpose of measuring the financial covenant set forth in Section 6.06(a) for such fiscal quarter
    and the applicable subsequent periods which include such fiscal quarter or applicable period for which such Equity Cure was exercised,
    and not for any other purpose under this Agreement; and	 
	 	 	 	 
	 	(b)	if, after
    giving effect to the foregoing recalculations, Borrower shall then be in compliance with the requirements of the applicable financial
    covenant set forth in Section 6.06(a), Borrower shall be deemed to have satisfied the requirements of the financial covenant
    set forth in Section 6.06(a) as of the relevant date of determination with the same effect as though there had been no failure
    to comply therewith at such date, and the applicable breach or default of the financial covenant set forth in Section 6.06(a)
    that had occurred shall be deemed cured for the purposes of this Agreement.”	 

 

(r)
The following defined terms in Annex I to the Credit Agreement are hereby amended and restated in their entirety to read as follows:

 

““Corporate
Guarantor” means, individually and collectively, (i) Parent, (ii) Trillium Healthcare – OPS, LLC (f/k/a Fairway Healthcare
Properties, LLC), (iii) Assisted 4 Living Consulting, LLC (f/k/a Trillium Healthcare Consulting, LLC), (iv) IANE Properties I, LLC, (v)
IANE Properties II, LLC, and (vi) Greenside Healthcare Properties, LLC, each a Florida limited liability company, except for Parent.

 

““Fixed
Charge Coverage Ratio” means the ratio of (a) EBITDAR, to (b) the sum of (i) the current portion of lease payments under Capital
Leases, plus (ii) the current portion of long-term debt (excluding Subordinated Debt), plus (iii) Tax Distributions paid, plus (iv) interest
expense paid in cash, plus (v) unfinanced capital expenditures, plus (vi) to the extent specifically permitted by Section 7.09 hereof,
Distributions paid, plus (vii) rent expense paid in cash, plus (viii) any payments of Subordinated Debt actually made, all as determined
for Borrower on a consolidated basis, in accordance with GAAP.”

 

““LIBOR
Rate” means an annual rate equal to, as a reference rate, the greater of (i) the annual rate reported as the London Interbank
Offer Rate applicable to ninety (90) day deposits of United States Dollars as reported in the Money Rates Section of The Wall Street
Journal on the date of determination and (ii) one percent (1.00%). If The Wall Street Journal is not published on such Business
Day or does not report such rate, such rate shall be as reported by such other publication or source as Lender may select. Notwithstanding
the foregoing, if (i) LIBOR is replaced or ceases to exist or be published by The Wall Street Journal, (ii) there is a material
disruption to LIBOR, (iii) there is a change in the methodology of calculating LIBOR or (iv) in the reasonable expectation of Lender,
any of the events specified in clause (i), (ii) or (iii) will occur, Lender shall in its sole discretion choose a replacement index for
LIBOR and make adjustments to applicable margins and related amendments to this Agreement such that, to the extent practicable, the all-in
interest rate based on the replacement index will be substantially equivalent to the all-in LIBOR Rate-based interest rate in effect
immediately prior to its replacement.”

 

    	7

     

    

 

““Parent”
means Assisted 4 Living, Inc., a Nevada corporation.”

 

““Revolving
Loan Commitment” means the Initial Revolving Loan Commitment plus the activated amount of any Additional Tranches. For the
avoidance of doubt, the aggregate Revolving Loan Commitment on the Second Amendment Effective Date shall be Seven Million and No/100
Dollars ($7,000,000.00), and if an Additional Tranche is activated pursuant to the terms of this Agreement, the Revolving Loan Commitment
shall increase by the amount of such activated Additional Tranche up to the Maximum Revolver Amount.”

 

(s)       The
following defined terms are hereby added to Annex I to the Credit Agreement in alphabetical order therein as follows:

 

““Activated
Facility Commitment” means the Initial Revolving Loan Commitment, plus any activated Additional Tranche.”

 

““Additional
Tranche” means, and “Additional Tranches” means the collective reference to, each additional amount of Revolving
Loans provided pursuant to Section 2.01(a) hereof in excess of the Initial Revolving Loan Commitment and each in an amount equal
to either Three Million and No/100 Dollars ($3,000,000.00) or Five Million and No/100 Dollars ($5,000,000.00), but in no event shall
(1) the sum of (i) the Initial Revolving Loan Commitment, plus (ii) the aggregate amount of all Additional Tranches exceed the Maximum
Revolver Amount, and (2) the Borrower activate an Additional Tranche equal to Three Million and No/100 Dollars ($3,000,000.00) more than
once.”

 

““Applicable
Margin” shall be, at any given time, as set forth in the following table:

 

	If the average monthly outstanding balance of the Revolving Loans during the immediately preceding three (3) months is:	 	Applicable Margin for all Revolving Loans:
	Equal to or less than Four Million and No/100 Dollars ($4,000,000.00)	 	 	4.50	%
	 	 	 	 	 
	Greater than Four Million and No/100 Dollars ($4,000,000.00) but less than or equal to Six Million and No/100 Dollars ($6,000,000.00) 
	 	 	4.35	%
	 	 	 	 	 
	Greater than Six Million and No/100 Dollars ($6,000,000.00) but less than or equal to Eight Million and No/100 Dollars ($8,000,000.00) 
	 	 	4.20	%
	 	 	 	 	 
	Greater than Eight Million and No/100 Dollars ($8,000,000.00) but less than or equal to Ten Million and No/100 Dollars ($10,000,000.00) 
	 	 	4.05	%
	 	 	 	 	 
	Greater than Ten Million and No/100 Dollars ($10,000,000.00) 
	 	 	3.90	%”

 

    	8

     

    

 

““Capital
Infusion” means, for any period of Borrower, the amount of any (i) capital investment or infusion of equity in Borrower by
any Person, including, without limitation, current or new Members or Affiliates, in the form of cash contributions, or (ii) Subordinated
Debt permitted hereunder and at all times subject to a Subordination Agreement in form and substance satisfactory to Lender in Lender’s
sole discretion. For the avoidance of doubt, any Capital Infusion of equity includes, without limitation, any capital raise by Borrower
which results in the issuance of Equity Interests.”

 

““Equity
Cure Period” has the meaning set forth in Section 8.02 hereof.”

 

““Equity
Cure” has the meaning set forth in Section 8.02 hereof.”

 

““Excluded
Subsidiary” means, individually and collectively, (i) Real Living Property Holdings, LLC, a Florida limited liability company,
(ii) Banyan Pediatric Care Centers – OPS, a Florida limited liability company, (iii) Banyan Pediatric Care Centers – Texas
OPS, a Texas limited liability company, and (iv) LOGAN Healthcare Properties, LLC, a Florida limited liability company, and each of their
direct and indirect wholly-owned subsidiaries.”

 

““Holding
Entity” means, individually and collectively, (i) IANE Properties I, LLC, a Florida limited liability company, (ii) IANE Properties
II, LLC, a Florida limited liability company, and (iii) Greenside Healthcare Properties, LLC, a Florida limited liability company.”

 

““Initial
Commitment Fee” has the meaning set forth in Section 2.09 hereof.”

 

““Initial
Revolving Loan Commitment” means an amount equal to Seven Million and No/100 Dollars ($7,000,000.00).”

 

““Maximum
Revolver Amount” means Twenty-Five Million and No/100 Dollars ($25,000,000.00).”

 

““Second
Amendment Effective Date” means September 30, 2021.”

 

3.
Representations and Warranties. Each Borrower represents and warrants to Lender that:

 

(a)
All warranties and representations made to Lender under the Credit Agreement and the Existing Loan Documents are true and correct as
to the date hereof.

 

(b)
The execution and delivery by each Borrower of this Amendment and the performance by it of the transactions herein contemplated (i) are
and will be within its powers, (ii) have been authorized by all necessary organizational action, and (iii) are not and will not be in
contravention of any order of any court or other agency of government, of law or any other indenture, agreement or undertaking to which
such Borrower is a party or by which the property of such Borrower is bound, or be in conflict with, result in a breach of, or constitute
(with due notice and/or lapse of time) a default under any such indenture, agreement or undertaking or result in the imposition of any
lien, charge or encumbrance of any nature on any of the properties of such Borrower.

 

(c)
This Amendment and any assignment, instrument, document, or agreement executed and delivered in connection herewith, will be valid, binding
and enforceable in accordance with its respective terms, subject to bankruptcy, insolvency and similar laws affecting the enforceability
of creditors’ rights generally and to general principles of equity, regardless of whether considered in a proceeding in equity
or at law.

 

(d)
No Event of Default or Default has occurred and is continuing under the Credit Agreement or any of the other Existing Loan Documents.

 

    	9

     

    

 

4.
Effectiveness Conditions. This Amendment shall be effective upon completion of the following conditions precedent (all documents
to be in form and substance satisfactory to Lender and Lender’s counsel):

 

(a)
Borrower shall deliver to Lender a fully executed copy of this Amendment and each of the documents set forth on the Closing Agenda attached
hereto as Exhibit A on or before the date hereof (or such later time as extended by Lender in its sole discretion);

 

(b)
Payment of (i) an amendment fee which Borrower hereby agrees Lender has fully earned and is nonrefundable as of the date hereof in an
amount equal to Seventy Thousand and No/100 Dollars ($70,000.00), (ii) all outstanding Expenses, including, without limitation, the outstanding
balance of the Initial Commitment Fee (which Borrower hereby agrees Lender has fully earned and is nonrefundable) owed by the Borrower
in an amount equal to Twenty-Five Thousand and No/100 Dollars ($25,000.00), and (iii) any and all Expenses associated with this Amendment;
and

 

(c)
Execution and/or delivery of all agreements, instruments and documents requested by Lender to effectuate and implement the terms hereof
and the Existing Loan Documents.

 

5.
Ratification of Existing Loan Documents. Except as expressly set forth herein, all of the terms and conditions of the Credit Agreement
and Existing Loan Documents are hereby ratified and confirmed and continue unchanged and in full force and effect. All references to
the Credit Agreement shall mean the Credit Agreement as modified by this Amendment.

 

6.
Release. By execution of this Amendment, Borrower acknowledges and confirms that it does not have any offsets, defenses or claims
arising out of or relating to this Amendment, the Credit Agreement or the Existing Loan Documents against Lender, or any of its subsidiaries,
affiliates, officers, directors, employees, agents, attorneys, predecessors, successors or assigns whether asserted or unasserted. To
the extent that such offsets, defenses or claims may exist, each Borrower, for itself and its successors, assigns, parents, subsidiaries,
affiliates, predecessors, employees, agents, heirs and executors, as applicable (collectively, “Releasors”), jointly
and severally, release and forever discharge Lender and its subsidiaries, affiliates, officers, directors, employees, agents, attorneys,
predecessors, successors and assigns, both present and former (collectively, the “Lender Affiliates”) of and from
any and all manner of actions, causes of action, torts, suits, debts, controversies, damages, judgments, executions, claims and demands
whatsoever, asserted or unasserted, in law or in equity, arising out of or relating to this Amendment, the Credit Agreement and the Existing
Loan Documents which Releasors ever had or now have against the Lender and/or Lender Affiliates, including, without limitations, any
presently existing claim or defense whether or not presently suspected, contemplated or anticipated.

 

7.
Security Interest. Each Borrower hereby confirms and agrees that all security interests and liens granted to Lender continue in
full force and effect and shall continue to secure the Obligations. All Collateral remains free and clear of any liens other than liens
in favor of Lender and Permitted Liens. Nothing herein contained is intended to in any way impair or limit the validity, priority and
extent of Lender’s existing security interest in and liens upon the Collateral.

 

8.
GOVERNING LAW. THIS AMENDMENT, AND ALL MATTERS ARISING OUT OF OR RELATING TO THIS AMENDMENT, SHALL BE GOVERNED BY AND CONSTRUED
IN ACCORDANCE WITH THE LAWS OF THE COMMONWEALTH OF PENNSYLVANIA, WITHOUT GIVING EFFECT TO PRINCIPLES OF CONFLICTS OF LAWS, AND SHALL
BE CONSTRUED WITHOUT THE AID OF ANY CANON, CUSTOM OR RULE OF LAW REQUIRING CONSTRUCTION AGAINST THE DRAFTSMAN.

 

9.
Counterparts. This Amendment may be executed in any number of counterparts, each of which when so executed shall be deemed to
be an original, and such counterparts together shall constitute one and the same respective agreement. Signature by facsimile or other
electronic means shall bind the parties hereto.

 

    	10

     

    

 

Signature
Page to Second Amendment to Credit Agreement

 

IN
WITNESS WHEREOF, this Amendment has been duly executed as of the day and year first above written.

 

	BORROWERS
    AND CORPORATE GUARANTORS:

     

    Address
    for notices to Borrowers:

     

    5115
    East SR 64

    Bradenton,
    LF 34208

    Attn:
    Louis Collier

    Email:LCollier@assisted4living.com

    Phone:
    855-668-3331

     
	TRILLIUM
    HEALTHCARE-OPS, LLC (f/k/a FAIRWAY HEALTHCARE PROPERTIES, LLC),

    ASSISTED
    4 LIVING, INC.,

    ASSISTED
    4 LIVING CONSULTING, LLC (f/k/a TRILLIUM HEALTHCARE CONSULTING),

    IANE
    PROPERTIES I, LLC,

    IANE
    PROPERTIES II, LLC,

    GREENSIDE
    HEALTHCARE PROPERTIES, LLC,

    FAIR
    OAKS RCF, LLC,

    CREST
    HAVEN CARE CENTER, LLC,

    PREMIER
    ESTATES 503, LLC,

    ELMWOOD
    CARE CENTER, LLC,

    ELMWOOD
    PE, LLC,

    PREMIER
    ESTATES 509, LLC,

    PREMIER
    ESTATES 507, LLC,

    PREMIER
    ESTATES 505, LLC,

    ROCK
    RAPIDS CARE CENTER, LLC,

    ROCK
    RAPIDS PE, LLC,

    PREMIER
    ESTATES 511, LLC,

    PREMIER
    ESTATES 502, LLC,

    PREMIER
    ESTATES 504, LLC,

    PREMIER
    ESTATES 506, LLC,

    NEW
    HAMPTON CARE CENTER, LLC,

    PREMIER
    ESTATES OF MUSCATINE, LLC,

    PREMIER
    ESTATES 508, LLC,

    PREMIER
    ESTATES OF TOLEDO, LLC,

    SUNNY
    KNOLL CARE CENTER, LLC,

    PREMIER
    ESTATES 510, LLC,

    NORTH
    PLATTE CARE CENTER, LLC,

    NORTH
    PLATTE PE, LLC,

    PREMIER
    ESTATES OF CRETE, LLC,

    PREMIER
    ESTATES OF FREMONT, LLC,

    PREMIER
    ESTATES OF KENESAW, LLC,

    PREMIER
    ESTATES OF PAWNEE, LLC,

    PREMIER
    ESTATES OF PIERCE, LLC,

    PREMIER
    ESTATES OF WEST POINT, LLC,

    REHABILITATION
    CENTER AT PARK PLACE, LLC, and

    PREMIER
    ESTATES OF DUBLIN, LLC

    

    

 

		 	By:	/s/
    Louis Collier
	 	 	Name:
    	Louis
    Collier
	 	 	Title:
    	Chief
    Executive Officer
	 	 	 	 
	 	 	As
    Chief Executive Officer of each of the above entities and, in such capacity, intending by this signature to legally bind each of
    the above entities

 

    	 

     

    

 

Signature
Page to Second Amendment to Credit Agreement

 

	RELEASED
    GUARANTORS:	 	TRILLIUM
    HEALTHCARE GROUP, LLC
	 	 	 	 
	 	 	By:	/s/
G. Shayne Bench
	 	 	Name:
    	G.
    Shayne Bench
	 	 	Title:
    	Treasurer
	 	 	 	 
	 	 	 	/s/
    Gregory Shayne Bench
	 	 	 	Gregory
    Shayne Bench
	 	 	 	 
	 	 	/s/ Shari C. Bench
	 	 	Shari C. Bench
	 	 	 	 
	 	 	/s/ Richard T. Mason
	 	 	Richard T. Mason
	 	 	 	 
	 	 	/s/ Christine L. Mason
	 	 	Christine L. Mason

 

    	 

     

    

 

Signature
Page to Second Amendment to Credit Agreement

 

	LENDER:

     

    

    
	 	GEMINO
    HEALTHCARE FINANCE, LLC d/b/a SLR HEALTHCARE ABL, a Delaware limited liability company
	Address
    for notices to Lender:	 	 	 
	 	 	 	 
	One
    International Plaza, Suite 220	 	By:	/s/
Stacy L. Allen
	Philadelphia,
PA 19113
	 	Name:
    	Stacy
    L. Allen
	Thomas
Schneider, CEO 
	 	Title:
    	Executive
    Vice President
	P:
(610) 870-5403 
	 	 	 
	F:
(610) 870-5401 
	 	 	 
	Email:
    tom.schneider@gemino.com	 	 	 

 

    	 

     

    

 

ANNEX
A

 

BORROWERS

 

1.
Fair Oaks RCF, LLC

2.
Crest Haven Care Center, LLC

3.
Premier Estates 503, LLC

4.
Elmwood Care Center, LLC

5.
Elmwood PE, LLC

6.
Premier Estates 509, LLC

7.
Premier Estates 507, LLC

8.
Premier Estates 505, LLC

9.
Rock Rapids Care Center, LLC

10.
Rock Rapids PE, LLC

11.
Premier Estates 511, LLC

12.
Premier Estates 502, LLC

13.
Premier Estates 504, LLC

14.
Premier Estates 506, LLC

15.
New Hampton Care Center, LLC

16.
Premier Estates of Muscatine, LLC

17.
Premier Estates 508, LLC

18.
Premier Estates of Toledo, LLC

19.
Sunny Knoll Care Center, LLC

20.
Premier Estates 510, LLC

21.
North Platte Care Center, LLC

22.
North Platte PE, LLC

23.
Premier Estates of Crete, LLC

24.
Premier Estates of Fremont, LLC

25.
Premier Estates of Kenesaw, LLC

26.
Premier Estates of Pawnee, LLC

27.
Premier Estates of Pierce, LLC

28.
Premier Estates of West Point, LLC

29.
Rehabilitation Center at Park Place, LLC

30.
Premier Estates of Dublin, LLC

31.
Premier Estates 520, LLC

32.
Premier Estates 521, LLC

33.
Premier Estates 522, LLC

34.
Premier Estates 523, LLC

35.
Premier Estates 524, LLC

36.
Premier Estates 525, LLC

37.
Premier Estates 526, LLCExhibit
10.15

 

***
Certain information has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful
if publicly disclosed.

 

AMENDMENT
TO STRATEGIC COLLABORATION AGREEMENT

 

This
AMENDMENT TO THE STRATEGIC COLLABORATION AGREEMENT (“Amendment”) is effective this 24th day of February 2021 (the
“Amendment Effective Date”) by and between THE UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER, with a place of business
located at 1515 Holcombe Blvd., Houston, TX 77030, USA (“MD Anderson”), a member institution of The University of
Texas System (“System”) and 4D PHARMA PLC, with a place of business located at 9 Bond Court Leeds LS1 2JZ, United
Kingdom (“Company”). MD Anderson and Company are sometimes collectively referred to herein as the “Parties”
and separately as a “Party.”

 

WHEREAS,
pursuant to that certain Strategic Collaboration Agreement made as of November 10, 2017 by and between MD Anderson and Company (the “Agreement”),
the Parties established a strategic collaboration whereby Company provides funding and in-kind support for one or more clinical studies
in Solid Tumours and Radiation Oncology to be conducted by MD Anderson.

 

WHEREAS,
the Parties now desire to amend the Agreement as set forth below.

 

NOW,
THEREFORE, in consideration of the mutual covenants, agreements and stipulations set forth herein, the receipt and legal sufficiency
of which are hereby mutually acknowledged, the Parties hereby agree as follows:

 

ARTICLE
I

DEFINITIONS

 

Unless
otherwise defined in this Amendment, initially capitalized terms used herein shall have the meanings given to them in the Agreement.

 

ARTICLE
II

AMENDMENTS
TO AGREEMENT

 

2.1
Section 1.2. The following sentence is hereby added to the Section 1.2 of the Agreement to the end thereof:

 

“For
clarity, the Parties agree that the Studies may include services to be performed by MD Anderson pursuant to a Study Order requesting
analysis of certain materials gathered from study sites participating in clinical studies related to those conducted by MD Anderson herein
(such clinical studies, the “Other Trial Site Studies”).”

 

***Certain
information, as identified by [***], has been excluded from this agreement because it is both (i) not material and (ii) would
be competitively harmful if publicly disclosed.

 

    	1

     

    

 

2.2
Section 1.4. The schedule in Section 1.4 is hereby deleted in its entirety and replaced with the following schedule:

 

	Milestone	 	Amount
    Due
	Upfront
    payment due upon execution of Agreement (20%)	 	[***]
    – Paid
	January
    10, 2019	 	[***]
    – Paid
	July
    10, 2021	 	$[***]
	January
    10, 2022	 	$[***]
	January
    10, 2023	 	$[***]
	January
    10, 2024	 	$[***]

 

2.3
Section 3.3. The first sentence of Section 3.3 of the Agreement is hereby deleted in its entirety and replaced with the following:

 

“From
time to time during the term, either Party (the “Transferring Party”) may supply the other Party (the “Receiving
Party”) with proprietary materials of the Transferring Party (other than Study Drug but specifically including any materials
Company provides to MD Anderson from other study sites participating in Other Trial Site Studies) (“Proprietary Materials”)
for use in the Study as may be further listed in the Study Order.”

 

2.4
Section 8.1. The first sentence of Section 8.1 of the Agreement is hereby deleted in its entirety and replaced with the following:

 

“The
term of this Agreement shall be eight (8) years following the Effective Date or until the Studies are completed, whichever is later,
unless terminated earlier in accordance with the provisions hereof.

 

2.5
Section 12.1. The first two sentences of Section 12.1 of the Agreement are hereby deleted in its entirety and replaced with the
following:

 

“MD
Anderson and/or Principal Investigator shall have the right to publish or publicly disclose, either in writing or orally, the Data and
results of the Study, provided that MD Anderson or Principal Investigator, as applicable, shall provide Company with a copy of any such
proposed publication or disclosure at least [***] prior to submission for publication or proposed disclosure. Within such [***] period,
Company shall review such proposed publication or disclosure for any Confidential Information of Company provided hereunder or potentially
patentable subject matter.”

 

***Certain
information, as identified by [***], has been excluded from this agreement because it is both (i) not material and (ii) would
be competitively harmful if publicly disclosed.

 

    	2

     

    

 

2.6
Section 12.4. Section 12.4 is hereby added to the Agreement and will state the following:

 

“MD
Anderson and Principal Investigator acknowledge that a Study may be a multi-centre study. Notwithstanding anything to the contrary herein,
in the event that a Study is a multi-centre study, any publication based on the results or data obtained at MD Anderson shall not be
made before the first multi-centre publication and shall be subject to this Section 12. If a publication concerns the analyses of sub-sets
of Data from such Study, the publication must make reference to the relevant multi-centre publication. After the multi-centre publication
or [***] after data base lock following completion, termination, or abandonment of the relevant study at all sites, whichever occurs
first, MD Anderson may itself publish the Data.”

 

ARTICLE
III

GENERAL

 

3.1
No Other Modifications. Except as specifically set forth in this Amendment, the terms and conditions of the Agreement shall remain
in full force and effect. No waiver, alteration or modification of any of the provisions of this Amendment shall be binding unless made
in writing and signed by the Parties by their respective officers thereunto duly authorized. The waiver by either Party of a breach or
a default of any provision of this Amendment by the other Party shall not be construed as a waiver of any succeeding breach of the same
or any other provision, nor shall any delay or omission on the part of either Party to exercise or avail itself of any right, power or
privilege that it has or may have hereunder operate as a waiver of any right, power or privilege by such Party.

 

3.2
Miscellaneous. This Amendment may be executed in any number of counterparts, each of which shall be deemed an original but all
of which together shall constitute one and the same instrument. This Amendment, once executed by a Party may be delivered via electronic
means of transmission and shall have the same force and effect as if it were executed and delivered by the Parties in the presence of
one another. This Amendment shall be governed by and construed in accordance with the laws of the State of Texas, United States without
regard to its conflicts of laws principles.

 

[signature
page to follow]

 

***Certain
information, as identified by [***], has been excluded from this agreement because it is both (i) not material and (ii) would
be competitively harmful if publicly disclosed.

 

    	3

     

    

 

IN
WITNESS WHEREOF, the Parties hereto have caused this Amendment to be executed as of the Amendment Effective Date by their duly authorized
representatives.

 

	THE
    UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER	 
	 	 	 
	By:
    	           	 
	 	 	 
	Name:	 	 
	 	 	 
	Title:	 	 
	 	 	 
	Date:
    	 	 

 

	4D
    PHARMA PLC	 
	 	 	 
	By:
    	      	 
	 	 	 
	Name:	 	 
	 	 	 
	Title:	 	 
	 	 	 
	Date:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}]]